Showing 111-120 of 1913 results for "".
Journal Club: Atopic Dermatitis Control Tool
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-atopic-dermatitis-control-tool/26734/Peter Lio, MD, talks with Lisa Swanson, MD, a board-certified dermatologist and pediatric dermatologist practicing in Boise, Idaho, about the Atopic Dermatitis Control Tool (ADCT). Highlighted in a recent study published in the British Journal of Dermatology, the ADCT has been said to provide patienJournal Club: Oral JAK Inhibitors in Moderate-to-Severe AD
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-oral-jak-inhibitors-moderate-severe-ad/24539/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a dermatologist at Seattle Children's Hospital, about nuanced differences in guideline-recommended use of oral JAK inhibitors in pediatric patients with moderate-to-severe atopic dermatitis (AD) provided in the Annals of Allergy, Asthma, and ImmunolJournal Club: Blocking IL-4/IL-13 vs JAK/STAT
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-blocking-il-4il-13-vs-jakstat/29101/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Editorial Board member Peter Lio, MD, about the Journal of Personalized Medicine article, "Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?"Journal Club: Comparing Recommendations from Different AD Guidelines
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-comparing-recommendations-from-different-ad-guidelines/24466/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a pediatric dermatologist at Seattle Children's Hospital, about some of the differences in recommendations from the Annals of Allergy, Asthma, and Immunology Joint Task Force AD guidelines, and the Journal of the American Academy of Dermatology (JAAAs New Jersey Goes, So Goes the Nation?
https://practicaldermatology.com/topics/practice-management/as-new-jersey-goes-so-goes-the-nation/20515/New Jersey's doctor gift ban may be the tip of the iceberg.Journal Club: Pediatric Treatment Adherence
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-pediatric-treatment-adherence/32401/Practical Dermatology Editorial Board members Lawrence Eichenfield, MD, FAAD, Jason Hawkes, MD, MS FAAD, discuss the article "Treatment Adherence in Pediatric Atopic Dermatitis: A Systemic Review," from Pediatric Dermatology as well as their favorite strategies for treatment adherence and the impactSCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. James Q. Del Rosso on Innovative Therapies
https://practicaldermatology.com/error/404/James Q. Del Rosso, DO, joins Joel Cohen, MD, to discuss innovation in the world of acne and rosacea, atopic dermatitis, psoriasis, alopecia areata, hidradenitis suppurativa, vitiligo, and more at Music City SCALE.SCALE 2024: Dr. Joel Cohen Interviews Dr. Saranya Wyles on Exosomes
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-joel-cohen-interviews-dr-saranya-wyles-exosomes/26364/Saranya Wyles, MD, PhD, joins Joel Cohen, MD, to discuss her research on exosomes at Music City SCALE.Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pClinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.